These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 28388572)

  • 1. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
    Villarreal DO; Chin D; Smith MA; Luistro LL; Snyder LA
    Oncotarget; 2017 Jun; 8(24):39117-39130. PubMed ID: 28388572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
    Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
    J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
    Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ
    J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
    Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
    J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
    Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
    Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
    Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
    Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
    [No Abstract]   [Full Text] [Related]  

  • 12. Rational design of anti-GITR-based combination immunotherapy.
    Zappasodi R; Sirard C; Li Y; Budhu S; Abu-Akeel M; Liu C; Yang X; Zhong H; Newman W; Qi J; Wong P; Schaer D; Koon H; Velcheti V; Hellmann MD; Postow MA; Callahan MK; Wolchok JD; Merghoub T
    Nat Med; 2019 May; 25(5):759-766. PubMed ID: 31036879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.
    Aranda F; Llopiz D; Díaz-Valdés N; Riezu-Boj JI; Bezunartea J; Ruiz M; Martínez M; Durantez M; Mansilla C; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
    Cancer Res; 2011 May; 71(9):3214-24. PubMed ID: 21402711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
    Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG
    Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
    Cohen AD; Diab A; Perales MA; Wolchok JD; Rizzuto G; Merghoub T; Huggins D; Liu C; Turk MJ; Restifo NP; Sakaguchi S; Houghton AN
    Cancer Res; 2006 May; 66(9):4904-12. PubMed ID: 16651447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
    Martínez-Usatorre A; Donda A; Zehn D; Romero P
    J Immunol; 2018 Jul; 201(2):792-803. PubMed ID: 29875150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.
    Avogadri F; Zappasodi R; Yang A; Budhu S; Malandro N; Hirschhorn-Cymerman D; Tiwari S; Maughan MF; Olmsted R; Wolchok JD; Merghoub T
    Cancer Immunol Res; 2014 May; 2(5):448-58. PubMed ID: 24795357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.
    Pruitt SK; Boczkowski D; de Rosa N; Haley NR; Morse MA; Tyler DS; Dannull J; Nair S
    Eur J Immunol; 2011 Dec; 41(12):3553-63. PubMed ID: 22028176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
    Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
    Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
    Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
    Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.